Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma

Clinical Cancer Research

Volumn 17, Issue 22, 2011, Pages 7093-7104

  Fang, Hua ^a,b   Harned, Theresa M ^a   Kalous, Ondrej ^a   Maldonado, Vanessa ^a   DeClerck, Yves A ^a,b   Reynolds, C Patrick ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE 9; CYTOCHROME C; FENRETINIDE; PROTEIN BAK; PROTEIN BAX; PROTEIN BAX ALPHA; PROTEIN BCL 2; PROTEIN BID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EVENT FREE SURVIVAL; FEMALE; HUMAN; IN VITRO STUDY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIPHENYL COMPOUNDS; CASPASES; CELL LINE, TUMOR; CYTOCHROMES C; DISEASE-FREE SURVIVAL; FEMALE; FENRETINIDE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, NUDE; NEUROBLASTOMA; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81255150499     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0578     Document Type: Article

References (50)

1. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79. (Pubitemid 29318861)
2. Matthay K, Villablanca JG, Seeger RC, Stram DO, Harris R, Ramsay NK, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-73. (Pubitemid 29480654)
3. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009;27:1007-13.
4. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-34.
5. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31. (Pubitemid 29094959)
6. Divinci A, Geido E, Infusini E, Giaretti W. Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide. Int J Cancer 1994;59:422-6. (Pubitemid 24331837)
7. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91:1138-46. (Pubitemid 29330552)
8. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, et al. Differential-effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma-cells - apoptosis versus differentiation. Cancer Res 1995;55:853-61.
9. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol 2000;35:597-602.
10. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds PC. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006;24:3423-30. (Pubitemid 46638899)
11. Marachelian A, Kang MH, Hwang K, Villablanca JG, Groshen S, Matthay KK, et al. Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma:NewApproaches to Neuroblastoma Therapy (NANT) Consortium trial [abstract]. J Clin Oncol 2009;27:10009.
12. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 2003;9:2032-9. (Pubitemid 36687622)
13. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-92. (Pubitemid 36860009)
14. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15: 1126-32.
15. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7:989-1000.
16. Lasorella A, Iavarone A, Israel MA. Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug-resistance. Cancer Res 1995;55:4711-6.
17. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, et al. Reduced expression of proapoptotic gene Bax Is associated with poor response rates to combination chemotherapy and shorter survival inwomen with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-8.
18. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81. (Pubitemid 40825512)
19. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, et al. A novel Bcl-2/Bcl-X-L/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007;26:2374-80. (Pubitemid 46572819)
20. Huang SB, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering bim and bak in human pancreatic cancer cells. Cancer Res 2008;68:2944-51. (Pubitemid 351556295)
21. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007;110:2057-66. (Pubitemid 47443923)
22. Tahir SK, Yang XF, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67: 1176-83.
23. Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, et al. The Bcl-2/Bcl-X-L family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007;13: 7191-8. (Pubitemid 350276906)
24. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 2008;100:580-95.
25. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998;58:5396-405. (Pubitemid 28551122)
26. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-93. (Pubitemid 32768583)
27. Masters JR, Thomson JA, Daly-Burns B, Reid YA, Dirks WG, Packer P, et al. Short tandemrepeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A 2001;98: 8012-7. (Pubitemid 32642678)
28. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, et al. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 1986;76:375-87. (Pubitemid 16119771)
29. Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, et al. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex. Clin Cancer Res 2007;13: 3079-86. (Pubitemid 46849585)
30. Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007;6:886-97. (Pubitemid 46554558)
31. Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 2005; 110:139-53.
32. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998; 391:96-9. (Pubitemid 28079223)
33. Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB, Hockenbery DM. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol 1997;138: 449-69. (Pubitemid 27323545)
34. Diaz GD, Li QJ, Dashwood RH. Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin. Cancer Res 2003;63:1254-61. (Pubitemid 36348703)
35. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989;24: 148-54. (Pubitemid 19163397)
36. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with 2 or more mutually exclusive and non-exclusive inhibitors. Eur J Biochem 1981;115:207-16.
37. Chou TC, Talalay P. Quantitative-analysis of dose-effect relationships - the combined effects of multiple-drugs or enzyme-Inhibitors. Adv Enzyme Regul 1984;22:27-55.
38. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatric Blood & Cancer 2007;49:928-40. (Pubitemid 350022448)
39. Kantari C, Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta 2011; 1813:558-63.
40. Gandhi L, Camidge DR, Ribeiro de OM, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011;29:909-16.
41. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149-59.
42. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183-92. (Pubitemid 41043974)
43. Letai A. BCL-2: found bound and drugged! Trends Mol Med 2005; 11:442-4. (Pubitemid 41415722)
44. LuoX,Budihardjo I,Zou H, Slaughter C,WangXD. Bid,a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-90. (Pubitemid 28391864)
45. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Millman C, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-X-L prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999;274:1156-63.
46. Yin XM, Wang K, Gross A, Zhao YG, Zinkel S, Klocke B, et al. Biddeficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999;400:886-91. (Pubitemid 29406726)
47. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing bak activation and bax translocation. Cancer Res 2007;67:782-91. (Pubitemid 46192219)
48. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X-L inhibitor ABT-737. Oncogene 2007;26:3972-9. (Pubitemid 46884293)
49. Moore VD, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117:112-21. (Pubitemid 46048458)
50. Wesarg E, Hoffarth S, Wiewrodt R, Kroell M, Biesterfeld S, Huber C, et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007;121:2387-94. (Pubitemid 350022407)